Voltage-gated sodium channel (Nav1.x) (Nav1.x)

Voltage-gated sodium channels (Nav1.x) are a family of nine transmembrane proteins (Nav1.1–Nav1.9) that are essential for the initiation and propagation of action potentials in excitable cells such as neurons and myocytes (Catterall, 2012). Each subtype has a distinct physiological role and tissue distribution; for example, Nav1.5 is critical for cardiac rhythm, while Nav1.7, Nav1.8, and Nav1.9 are key mediators of pain signaling in the peripheral nervous system (de Lera Ruiz & Kraus, 2015). These channels are the primary targets for several classes of drugs, including local anesthetics, anti-epileptics, and anti-arrhythmics, which generally act as pore blockers (Bagal et al., 2013). The term "Other Nav1.x voltage-gated sodium channel subtypes" is frequently used in drug discovery to refer to the collective group of isoforms that are not the primary therapeutic target, representing potential sites for off-target toxicity. Because of the high structural similarity between subtypes, achieving selectivity is a major challenge, and unintended inhibition of "other" subtypes can lead to severe adverse effects like cardiac arrhythmias or central nervous system dysfunction (Eijkelkamp et al., 2012).

Other names

Voltage-gated sodium channel familySodium channel alpha subunitSCN familyNav1.1-Nav1.9

Inhibition of sodium ion influx through the pore-forming alpha subunit, typically by stabilizing the inactivated state of the channel to prevent repetitive firing (Catterall, 2012; de Lera Ruiz & Kraus, 2015).